Idorsia Net Income Over Time
| IDIA Stock | CHF 3.97 0.11 2.85% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Idorsia Performance and Idorsia Correlation. Idorsia |
Cross Equities Net Income Analysis
Compare Idorsia and related stocks such as Basilea Pharmaceutica, PolyPeptide Group, and Kuros Biosciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BSLN | (59 M) | (57.6 M) | (53 M) | (33 M) | (41.5 M) | (61.6 M) | (51.3 M) | (19.4 M) | (31.4 M) | (22.4 M) | (14.7 M) | (6.8 M) | 12.1 M | 10.5 M | 77.6 M | 89.2 M | 93.7 M |
| PPGN | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 25.7 M | 31.3 M | 47.3 M | 7.8 M | (51.4 M) | (19.6 M) | (17.6 M) | (16.7 M) |
| KURN | (23.9 M) | (18.8 M) | (9.2 M) | (30.8 M) | (34 M) | 6.2 M | (19.7 M) | (16.5 M) | (11.7 M) | (11.3 M) | (11.5 M) | (7.5 M) | (14.6 M) | (13.7 M) | (3.7 M) | (4.3 M) | (4.5 M) |
| MOLN | 7.1 M | 7.1 M | 7.1 M | 7.1 M | (2.3 M) | (148.8 K) | (18.6 M) | (25.4 M) | (37 M) | (36.3 M) | (62.8 M) | (63.8 M) | 117.9 M | (62 M) | (54 M) | (48.6 M) | (46.2 M) |
| SANN | (28.3 M) | (27.8 M) | (31.4 M) | (5.8 M) | (7.5 M) | 5.9 M | (35.4 M) | (51.5 M) | (54.2 M) | (19 M) | (67.7 M) | (55.5 M) | (71.1 M) | 54.8 M | (42 M) | (37.8 M) | (39.7 M) |
| MED | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 3.3 M | 866.5 K | 4.2 M | 2.1 M | (943.6 K) | 6.8 M | (5.8 M) | 619 K | 3.5 M | 3.2 M | 1.8 M |
| NWRN | (14.9 M) | (6.4 M) | (2.4 M) | (7.1 M) | (10.1 M) | (22.8 M) | (15.2 M) | (5.3 M) | (15 M) | (20.2 M) | (21 M) | (14.9 M) | (17.5 M) | (16.2 M) | 15.8 M | 18.2 M | 19.1 M |
| ADXN | (20.5 M) | (31.1 M) | (27 M) | (14.5 M) | (1.8 M) | (4.2 M) | (3.1 M) | (3.3 M) | (1.6 M) | (14.8 M) | (12.9 M) | (15.4 M) | (20.8 M) | (10.6 M) | 7.1 M | 8.1 M | 8.5 M |
| COPN | (2.2 M) | 7.6 M | 19.3 M | 68.7 M | 73.3 M | 248.2 M | 19.3 M | (32.4 M) | (18.1 M) | (24.5 M) | (7.9 M) | 21.7 M | 17.2 M | (4.9 M) | 133.2 M | 153.2 M | 160.9 M |
Idorsia and related stocks such as Basilea Pharmaceutica, PolyPeptide Group, and Kuros Biosciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Idorsia financial statement analysis. It represents the amount of money remaining after all of Idorsia operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Idorsia | IDIA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Hegenheimermattweg 91, Allschwil, |
| Exchange | SIX Swiss Exchange |
CHF 3.97
Additional Tools for Idorsia Stock Analysis
When running Idorsia's price analysis, check to measure Idorsia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Idorsia is operating at the current time. Most of Idorsia's value examination focuses on studying past and present price action to predict the probability of Idorsia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Idorsia's price. Additionally, you may evaluate how the addition of Idorsia to your portfolios can decrease your overall portfolio volatility.